Original from: 360DX

PamGene International said Tuesday that the European Innovation Council's Accelerator program will provide €7.5 million ($8.2 million) in funding to develop and market the firm's prognostic test for immunotherapy response in metastatic cancer treatment.

The Netherlands-based firm said the test will be designed for use on its CE-IVD-marked IOpener testing instrument, which profiles host immune cell activity using multiplex peptide microarrays to predict patient response to immunotherapy. John Groten, PamGene's managing director, said in a statement that the award will let the firm carry out clinical utility studies in key countries in Europe and accelerate partnerships on commercialization activities.

The firm said it was one of 51 award winners, and a full list of award recipients was not immediately available.

PamGene has been working to expand its line of liquid biopsy assays ahead of commercialization in the US, having secured in July 2022 CE-IVD marking for its IOpener blood tests for patients with melanoma or non-small cell lung cancer.

Source: PamGene Awarded €7.5M for Metastatic Cancer Immunotherapy Response Test